{"task_id": "64cdc9f9916eae8a", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 141/464)", "text": "unoglobulin, ferritin, Fe,\n128\nAcute Liver Failure\n\n--- Page 150 ---\nINVESTIGATIONS (CONT\u2019D)\nTIBC, % sat, ceruloplasmin, a1 antitrypsin, AFP,\nantitransglutaminase antibody, lipase, amylase,\nLDH, haptoglobin, acetaminophen, CK, TSH\n\u0002 ERCP/MRCP\n\u0002\nGASTROSCOPY\n\u0002\nLIVER BIOPSY\nDIAGNOSTIC AND PROGNOSTIC ISSUES\n\" AST/SGOT\ndo panel of liver function tests. If\nisolated rise, consider non hepatic causes. Otherwise,\nsame as ALT workup. AST >ALT suggests alcoholic\nliver disease, fatty liver, or cirrhosis\n\" ALT/SGPT\nif symptomatic and presence of risk\nfactors for liver disease, liver dysfunction (# albumin,\n\" INR, \" bili), \" ALT or AST >3\u0004 upper limit of normal,\nor \" ALT >6 months, consider basic workup including\nabdominal U/S with dopplers, viral serologies, ANA,\nASMA, quantitative Ig, ceruloplasmin, iron studies, anti\ntransglutaminase antibody, and possibly liver biopsy\n\" ALP/BILI\nask about pain, symptoms of infiltrative\ndisease, or IBD. To confirm liver involvement, perform\nbilirubin fractionation, GGT, 5\u2019NT, abdominal U/S,\nAMA, and quantitative Ig. Consider MRCP/ERCP and\nliver biopsy\nMONITORING\nINR and bilirubin are much more use\nful to monitor liver function compared to transaminases\nSURVIVAL IN ACUTE HEPATIC FAILURE\n35% in\nhyperacute, 7% in acute, and 14% subacute\nMANAGEMENT OF ACUTE LIVER FAILURE\nSYMPTOM CONTROL\n\u0002\nACUTE\nABC, O2, IV hydration\n\u0002\nELEVATED\nINTRACRANIAL\nPRESSURE\nfor\ncerebral\nedema, consider prophylactic phenytoin, raise\nhead of bed, hyperventilate, dexamethasone,\nmannitol, avoid excessive fluids\n\u0002\nSEPSIS\nantibiotics\n\u0002\nCOAGULOPATHY\nvitamin K 10 mg IV/PO, FFP 2 4 U\nIV (only if active bleeding or invasive procedures,\nor difficult to follow INR afterward)\n\u0002\nACUTE RENAL FAILURE\nsupportive renal replace\nment. Consider midodrine, octreotide, and albumin\n\u0002\nENCEPHALOPATHY\nprotein intake up to 1 g/kg/day.\nLactulose 30 g PO QID PRN titrate to 2 4 bowel\nmovements/day\n\u0002\nACIDOSIS\nD10W\nwith\n1 2\namp\nNaHCO3\nat\n150 250 mL/h IV. Give with caution as risk of\ncerebral edema with increased fluid\n\u0002\nHYPOGLYCEMIA\nD10W, tube feed, TPN\n\u0002\nDETOXIFICATION\nN acetylcysteine\n150\nmg/kg\nIV (\u000660 mL) in 200 mL D5W over 1 h, then\n50 mg/kg (\u000620 mL) in 500 mL D5W over 4 h,\nthen 100 mg/kg (\u000640 mL) in 1L D5W over 16 h.\nAlternatively, N acetylcysteine 140 mg/kg PO/NG,\nMANAGEMENT OF ACUTE LIVER FAILURE (CONT\u2019D)\nfollowed by 70 mg/kg q4h for 17 doses. May con\ntinue N acetylcysteine until INR normalized\nPREVENTION\nhepatitis B vaccine (0, 1, 6 months),\nHBIG (post exposure), hepatitis A vaccine (see p. 270)\nTREAT UNDERLYING CAUSE\nhepatitis B (if acute\nliver failure from HBV, provide supportive care only\nwithout active HBV treatment). Hepatitis C (pegy\nlated interferon \b ribavirin). Alcoholic hepatitis\n(abstinence,\nnutrition,\nprednisolone\n40\nmg\nPO\n\u000428days but avoid if pancreatitis, GI bleed, renal\nfailure, or active infection; pentoxifylline 400 mg PO\nTID \u000428 days, S adenosylmethionine 1200 mg PO\ndaily \u00042 years). Autoimmune hepatitis (steroid).\nWilson\u2019s disease (D penicillamine)\nLIVER TRANSPLANT\npatients with fulminant liver\nfailure should be transferred to acute care centers\nwith liver transplant expertise\nTREATMENT ISSUES\nLIVER TRANSPLANT\n\u0002\nALLOCATION\nbased on ABO blood type, body size,\nwait designation, and degree of urgency\n\u0002 KING\u2019S COLLEGE CRITERIA FOR TYLENOL OVERDOSE\nACUTE HEPATIC FAILURE (rule of 3\u2019s)\neither arterial\npH <7.3 or grade III or IV encephalopathy, plus Cr\n>300 mmol/L [>3.3 mg/dL], plus INR >6\n\u0002 KING\u2019S COLLEGE CRITERIA FOR NON-TYLENOL ACUTE\nHEPATIC FAILURE\nINR >3 or any 3 of following:\nage <10 or >40, non A non B hepatitis, halothane\nhepatitis, idiosyncratic drug reactions, duration of\njaundice before onset of encephalopathy >7 days,\nINR >1.5, bilirubin >308 mmol/L [179 mg/dL]\n\u0002\nCONTRAINDICATIONS\nmalignancy (except hepato\ncellular carcinoma), irreversible cardiopulmonary\ncomorbidities,\nneuropsychiatric\ncomorbidities,\nsepsis, substance abuse, non compliance, HIV\nSPECIFIC ENTITIES\nAST/ALT\nTHOUSAND\nCLUB\nviral\nhepatitis,\nischemic liver (hypotension, hypoxia, sepsis), drugs/\ntoxins (acetaminophen/paracetamol), autoimmune\nhepatitis, gallstone disease (acute bile duct obstruc\ntion), acute Budd Chiari syndrome, hepatic artery\nligation\nALCOHOLIC LIVER DISEASE\n\u0002\nSUBTYPES\nfatty liver, alcoholic hepatitis, micro\nnodular cirrhosis\n\u0002\nDIAGNOSIS\nAST:ALT = 2:1 (low ALT activity due to\nalcohol related pyridoxal 5 phosphate deficiency),\nrare for AST to be >8\u0004 normal and for ALT to be\n>5\u0004 normal. GGT \", ALP \", bilirubin \"\n\u0002\nTREATMENTS\nabstinence, nutrition, prednisolone\n40 mg PO \u000428 days, pentoxifylline 400 mg PO\nTID \u00044 weeks, S adenosylmethionine 1200 mg PO\ndaily \u00042 years\nAcute Liver Failure\n129", "text_length": 4637, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 141/464)", "type": "chunk", "chunk_index": 140, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.439818", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.440588", "status": "complete", "chunks_added": 3}